Fox Run Management L.L.C. bought a new position in Dynavax Technologies Co. (NASDAQ:DVAX) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 13,750 shares of the biopharmaceutical company’s stock, valued at approximately $257,000.
Several other hedge funds have also recently modified their holdings of the business. Schwab Charles Investment Management Inc. lifted its stake in shares of Dynavax Technologies by 17.5% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 276,430 shares of the biopharmaceutical company’s stock worth $5,170,000 after purchasing an additional 41,120 shares during the last quarter. Creative Planning lifted its stake in shares of Dynavax Technologies by 52.1% during the 4th quarter. Creative Planning now owns 230,848 shares of the biopharmaceutical company’s stock worth $4,317,000 after purchasing an additional 79,025 shares during the last quarter. Vident Investment Advisory LLC raised its stake in Dynavax Technologies by 3.1% in the third quarter. Vident Investment Advisory LLC now owns 150,258 shares of the biopharmaceutical company’s stock valued at $3,231,000 after buying an additional 4,553 shares during the last quarter. First Republic Investment Management Inc. purchased a new stake in Dynavax Technologies in the third quarter valued at about $2,414,000. Finally, Crawford Lake Capital Management LLC purchased a new stake in Dynavax Technologies in the third quarter valued at about $1,481,000. Institutional investors and hedge funds own 68.60% of the company’s stock.
A number of research analysts have recently weighed in on DVAX shares. BidaskClub raised Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Monday, February 5th. Zacks Investment Research lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. ValuEngine lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Cantor Fitzgerald raised their target price on Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Thursday, November 9th. Finally, Cowen reiterated a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Dynavax Technologies currently has a consensus rating of “Hold” and an average price target of $25.17.
Shares of Dynavax Technologies Co. (NASDAQ DVAX) opened at $16.95 on Tuesday. The stock has a market capitalization of $1,030.00, a price-to-earnings ratio of -8.65 and a beta of 1.08. Dynavax Technologies Co. has a one year low of $3.90 and a one year high of $24.45.
In related news, insider Robert Coffman sold 7,500 shares of the business’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total transaction of $141,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP David Louis Johnson sold 3,092 shares of the business’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $18.60, for a total value of $57,511.20. Following the transaction, the vice president now directly owns 7,780 shares of the company’s stock, valued at $144,708. The disclosure for this sale can be found here. 2.90% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/13/fox-run-management-l-l-c-acquires-new-position-in-dynavax-technologies-co-dvax.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.